India has got another success in the war against Corona. The country's second indigenous Covid-19 vaccine has shown good results in human trials. The Central Drugs Laboratory (CDL) Kasauli, which approves the vaccine confirmed this on its website. Zydus Cadila's vaccine ZyCoV-D has proven effective in trials on children 12 years and above.
The company sent batches of the vaccine to Kasauli for human trials. Zydus Cadila is in high spirits after completing Phase III trials at CDL. It has sought approval from the Drug Controller General of India (DCGI) for emergency use. Zydus Cadila's Zycov-D vaccine based on indigenous technology is a three-dose vaccine. As soon as the license is cleared, the company will again send the public batch to the Central Drugs Laboratory for testing. After getting the final approval from the Central Drugs Laboratory, the company will launch India's second domestic vaccine in the market.
It is worth noting that the vaccine, which is manufactured, imported, exported from CDL Kasauli in India, is launched in the market only after getting approval. The Covid-19 vaccine of Covishield, Covaccine, Sputnik-V has been made part of the vaccination campaign in the country. The Xycov-D DNA-based Covid-19 vaccine is a three-dose vaccine and can be administered at an interval of 4–4 weeks. After the first dose of the Zykov-D Covid - 19 vaccine, a second dose should be taken on the 28th day, and the third dose should be administered on the 56th day.
In DNA technology, the genetic code of the coronavirus is used, which activates the immune system in the body of the vaccinated. The passing of the vaccine in the trial amid fears of a third wave of corona will further boost the pace of the vaccination campaign. It is said that based on the data submitted by Zydus Cadila, the expert committee can approve the vaccine in a few days.
Check out below Health Tools-
Calculate Your Body Mass Index ( BMI )